News
The day at a glance · 3 min read
Mood · Selective
+15
Sentiment, −100 to +100
Sanofi/Regeneron upfront payment
$1B
Total deal potential
$8B
Tilrekimig EASI-75 reduction
75%
Key driverMajor Phase 3 readout for Eli Lilly's oral GLP-1 and multi-billion dollar licensing expansion offset by broad healthcare sector weakness
Daily briefHealthcare· Money365.Market AI ·

Lilly GLP-1 Hits Phase 3 Goal; Regeneron Inks $8B Deal

Eli Lilly's Foundayo meets cardiovascular safety endpoint while Sanofi expands immunology alliance with Regeneron for up to $8 billion

Big Pharma & Biotech

Bullish
LLYREGNPFEBMY
Eli Lilly and Company (LLY) announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating Foundayo (orforglipron), the company's oral GLP-1 medicine, compared to titrated insulin glargine in adults with type 2 diabetes and obesity or overweight at increased cardiovascular risk. In the trial, which is the largest and longest study of this medicine in type 2 diabetes to date, Foundayo demonstrated non-inferior risk of major adverse cardiovascular events alongside sustained A1C reduction and weight loss.
Sanofi and Regeneron Pharmaceuticals (REGN) expanded their global alliance with multiple next-generation, long-acting immunology antibodies in a deal worth up to $8 billion.
Regeneron (REGN) will receive $1 billion upfront with potential for up to an additional $7 billion in future milestone payments, with the companies to equally share development and commercialization costs as well as any future profits. The partnership adds REGN20423, a clinical-stage long-acting IL-13 monoclonal antibody invented and developed by Regeneron, along with a long-acting IL-4xIL-13 bispecific and two other long-acting preclinical antibodies from Regeneron.
Pfizer Inc. (PFE) presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis. The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75 (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo.
Bristol Myers Squibb (BMY) received U.S. FDA approval for an expanded indication for CAMZYOS (mavacamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients.

MedTech & Diagnostics

Neutral

Biomarkers market 2026

$67.95B

Biomarkers market 2031

$112.10B+10.5% CAGR

Disposable sensors market 2026

$11.86B

Disposable sensors market 2031

$16.13B+6.4% CAGR

Radiation detection market 2026

$3.80B

Radiation detection market 2031

$5.68B+8.4% CAGR
ABTTMO
The global biomarkers market is projected to grow from $67.95 billion in 2026 to $112.10 billion by 2031, registering a 10.5% CAGR, according to market research profiling Roche, Abbott Laboratories (ABT), Thermo Fisher Scientific (TMO) and Qiagen. Growth is driven by precision medicine, companion diagnostics, AI, bioinformatics, digital pathology and multi-omics technologies, with predictive biomarkers leading the efficacy segment in 2025 and immunoassays holding the largest technology share.
The global disposable medical device sensors market is projected to grow from $11.86 billion in 2026 to $16.13 billion by 2031, registering a 6.4% CAGR, according to market research profiling Abbott (ABT), Roche, Medtronic and GE HealthCare. Growth is driven by chronic and infectious diseases, remote patient monitoring, point-of-care diagnostics, wearable devices, home healthcare and infection-prevention needs, with biosensors currently leading the market while strip sensors are expected to gain the largest share.
The global radiation detection, monitoring and safety market is projected to grow from $3.80 billion in 2026 to $5.68 billion by 2031, at an 8.4% CAGR, according to market research profiling Fortive, Thermo Fisher Scientific (TMO) and Mirion Technologies. Growth is driven by expanding medical imaging and radiotherapy, nuclear energy investments, regulatory requirements and security concerns, with detection and monitoring products and radiation detectors leading the market while Asia Pacific is set for significant growth.

Healthcare Sector Valuation

Neutral

JNJ closing price

$264.74+43% YoY

Market capitalization

$638B

Operating margin

29.19%
JNJ
Johnson & Johnson (JNJ) closed at $264.74 on September 30, within a few percent of its record and 43% higher than a year ago. The company is worth $638 billion and turns 29.19% of its $97.93 billion in revenue into operating profit.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy